188 related articles for article (PubMed ID: 8103188)
21. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer.
Schwab M; Amler LC
Genes Chromosomes Cancer; 1990 Jan; 1(3):181-93. PubMed ID: 1982063
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas.
Fong CT; White PS; Peterson K; Sapienza C; Cavenee WK; Kern SE; Vogelstein B; Cantor AB; Look AT; Brodeur GM
Cancer Res; 1992 Apr; 52(7):1780-5. PubMed ID: 1551108
[TBL] [Abstract][Full Text] [Related]
23. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
24. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
26. Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.
Papp J; Csokay B; Bosze P; Zalay Z; Toth J; Ponder B; Olah E
Br J Cancer; 1996 Nov; 74(10):1592-7. PubMed ID: 8932340
[TBL] [Abstract][Full Text] [Related]
27. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
28. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
29. Co-amplification of c-myc and c-erbB-2 oncogenes in a poorly differentiated human gastric cancer.
Tsuchiya T; Ueyama Y; Tamaoki N; Yamaguchi S; Shibuya M
Jpn J Cancer Res; 1989 Oct; 80(10):920-3. PubMed ID: 2575609
[TBL] [Abstract][Full Text] [Related]
30. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
Berns EM; Klijn JG; van Staveren IL; Portengen H; Noordegraaf E; Foekens JA
Eur J Cancer; 1992; 28(2-3):697-700. PubMed ID: 1350457
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification.
Fong CT; Dracopoli NC; White PS; Merrill PT; Griffith RC; Housman DE; Brodeur GM
Proc Natl Acad Sci U S A; 1989 May; 86(10):3753-7. PubMed ID: 2566996
[TBL] [Abstract][Full Text] [Related]
33. Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes.
Takita K; Sato T; Miyagi M; Watatani M; Akiyama F; Sakamoto G; Kasumi F; Abe R; Nakamura Y
Cancer Res; 1992 Jul; 52(14):3914-7. PubMed ID: 1617666
[TBL] [Abstract][Full Text] [Related]
34. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome.
Scheurlen WG; Schwabe GC; Joos S; Mollenhauer J; Sörensen N; Kühl J
J Clin Oncol; 1998 Jul; 16(7):2478-85. PubMed ID: 9667267
[TBL] [Abstract][Full Text] [Related]
36. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
37. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer.
Kreipe H; Feist H; Fischer L; Felgner J; Heidorn K; Mettler L; Parwaresch R
Cancer Res; 1993 Apr; 53(8):1956-61. PubMed ID: 8096798
[TBL] [Abstract][Full Text] [Related]
38. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe.
Joos S; Scherthan H; Speicher MR; Schlegel J; Cremer T; Lichter P
Hum Genet; 1993 Feb; 90(6):584-9. PubMed ID: 8383093
[TBL] [Abstract][Full Text] [Related]
39. [Proto-oncogene C-erbB-2 and human cancer].
Toyoshima K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):309-14. PubMed ID: 1968737
[TBL] [Abstract][Full Text] [Related]
40. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
